Transcode Therapeutics (RNAZ) Amortizatization of Intangibles (2023 - 2025)
Transcode Therapeutics' (RNAZ) quarterly Amortizatization of Intangibles came in at $37731.0 in Q1 2025, down 65.54% on a YoY basis from $109483.0 in Q1 2024, and down 66.46% quarter-over-quarter from $112509.0 in Q4 2024.
Analysis
Transcode Therapeutics (RNAZ) Amortizatization of Intangibles (2023 - 2025) Analysis & Trends
Transcode Therapeutics (RNAZ) has reported Amortizatization of Intangibles for 3 consecutive years, with $37731.0 the latest figure, recorded in Q1 2025.
- For the quarter ending Q1 2025, Amortizatization of Intangibles fell 65.54% year-over-year to $37731.0; the trailing twelve-month figure through Dec 2025 stood at $37731.0 (down 91.5% YoY), and the FY2025 full-year result was $37731.0, down 91.5% from the prior year.
- Amortizatization of Intangibles eased to $37731.0 in Q1 2025 per RNAZ's latest filing, from $112509.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $112509.0 in Q4 2024 and bottomed at $37731.0 in Q1 2025.
- Historically, Amortizatization of Intangibles has averaged $97217.4 across 3 years, with a median of $108518.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Amortizatization of Intangibles jumped 55.17% in 2024, then sank 65.54% in 2025.
- Over 3 years, Amortizatization of Intangibles stood at $108518.0 in 2023, then grew by 3.68% to $112509.0 in 2024, then plunged by 66.46% to $37731.0 in 2025.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $37731.0, $112509.0, and $111490.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 600.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 1.39 Mn |
| 10 | Transcode Therapeutics | 1.63 Mn | 1.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 37,731.00 |
| Dec 31, 2024 | 112,509.00 |
| Sep 30, 2024 | 111,490.00 |
| Jun 30, 2024 | 110,481.00 |
| Mar 31, 2024 | 109,483.00 |
| Dec 31, 2023 | 108,518.00 |
| Sep 30, 2023 | 107,565.00 |
| Jun 30, 2023 | 106,621.00 |
| Mar 31, 2023 | 70,559.00 |